Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a share loss) and a surge in revenue to $95.47 million  (against […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
